ARIAD: European Commission Endorses Iclusig's Approved Indications - Quick Facts

(RTTNews) - ARIAD Pharmaceuticals Inc. (ARIA) announced the European Commission (EC) has endorsed the final opinion adopted by the Committee for Medicinal Products for Human Use (CHMP) on Iclusig (ponatinib) following recommendations made by the Pharmacovigilance Risk Assessment Committee. The company said this concludes the European Article 20 review of Iclusig.

"With this final step in the review of Iclusig in Europe now complete, we will continue to focus our efforts on completing pricing and reimbursement in the remaining European countries this year and ensuring that Iclusig is available to all appropriate Philadelphia-chromosome positive leukaemia patients," said Jonathan Dickinson, general manager, ARIAD Pharmaceuticals (Europe).